To prospectively study the response to to phlebotomy therapy in patients with hereditary hemochromatosis using changes in the MCV/hemoglobin as the primary monitoring guide for the pace of iron-depletion, to compare the efficacy of the MCV gu...

To prospectively evaluate the effect of maintaining a long-term state of borderline iron-limited erythropoiesis (MCV 1-3% below baseline) on the frequency of phlebotomy during the maintenance phase oftherapy and on the progression of hemoc...

To establish a program to make blood therapeutically withdrawn fromhemochromatosis subjects available for allogeneic transfusion to patients in the Clinical Center, NIH.

To prospectively evaluate the effect of maintaining a long-term state of iron-limited erythropoiesis on the progression of hemochromatosis-associated cirrhosis.

99999999

All

15 Years and older (Child, Adult, Older Adult)

NCT00007150

01004501-CC-0045

December 7, 2000

December 11, 2000

August 13, 2018

National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland, United States